Human Trials

ObsEva completes phase 1 first-in-women study of OBE022 to treat preterm labor

ObsEva has completed a Phase 1 single and multiple ascending dose study of OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2α, or PGF2α, receptor antagonist for the treatment of preterm labor in weeks 24 to 34 of pregnancy.

Debiopharm unveils positive phase 2 trial with Debio 1450 in ABSSSI patients

Debiopharm International has unveiled positive results from a large Phase II study of the staphylococcal-selective antibiotic Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

Seattle Genetics starts phase 1 trial of SGN-CD352A in relapsed or refractory multiple myeloma

Seattle Genetics has enrolled the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma (MM).

NewVac’s ovarian cancer combination meets primary endpoints in phase II trial

NewVac has met all primary endpoints in the Phase II Clinical Trial of Quisinostat, novel selective oral histone deacetylase (HDAC1) inhibitor, which the company licensed from Janssen Pharmaceutica.